The 3CTN governance structure provides scientific and operational oversight to ensure the network operates effectively and efficiently with transparent decision-making processes.
The governance structure is comprised of the following committees:
- Management Committee;
- Executive Committee;
- Funders Oversight Committee; and
- Scientific Advisory Board.
Each committee is representative of stakeholders across Canada and their respective interests and priorities. In Phase I, the committees are structured in a way that will facilitate the development of the 3CTN business plan. In Phase II, committee membership may be modified as required to govern the network and are structured in a way to reflect the new 3CTN Strategic Plan for 2018-2022.
Chaired by Dr. Ian Tannock, the Management Committee is responsible for the operational management of the Network.
Management Committee responsibilities include:
- The oversight of processes for implementing 3CTN scientific and operational objectives;
- Ensuring 3CTN deliverables for cancer clinical trials;
- Promoting the necessary collaborations and communication;
- Reviewing finances, milestones and deliverables against projections;
- Approving the annual budget for the network;
- Reporting to funders.
The Executive Committee will act on behalf of the Management Committee (MC) on urgent matters arising between regular MC meetings in cases where it is not possible to convene a meeting of the MC or have quorum, and will act in other matters as delegated by the Management Committee.
Scientific Advisory Board
The Scientific Advisory Board is responsible for advising the network on strategic priorities, policies and trends.
Scientific Advisory Board responsibilities include:
- Making recommendations for the network’s strategic priorities for trials and activities;
- Evaluating the progress of the network at 18 and 36 months;
- Advising on policies and trends in health care, science, and technology related to trials.